1 April 2004
National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]
Summary,

GUIDELINE OBJECTIVE(S)

To assess the effectiveness and cost-effectiveness of zaleplon, zolpidem and zopiclone for the short-term management of insomnia

TARGET POPULATION

Adult patients with insomnia

INTERVENTIONS AND PRACTICES CONSIDERED

Hypnotic drug therapy:

1. Non-benzodiazepine hypnotics
* Zaleplon (Sonata®)
* Zolpidem (Stilnoct®)
* Zopiclone (Zimovane®)
2. Benzodiazepine hypnotics

MAJOR OUTCOMES CONSIDERED

* Clinical effectiveness (e.g., sleep onset latency, total sleep duration, number of awakenings, quality of sleep, rebound insomnia)
* Cost-effectiveness
* Adverse effects of treatment